Novartis stock pre-market at EUR 124.76: minus 0.42 percent
Published on 10/06/2026 at 07:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock was at EUR 124.76 pre-market at 7:49 a.m. CEST on October 6, 2026, according to Lang & Schwarz. That was minus 0.42 percent versus the EUR 125.29 prior close at Lang & Schwarz on October 5, 2026.
Novartis before the Xetra open
The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Novartis stock.
Dated company development
In a September 18, 2026, press release, Novartis said it had received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for Cosentyx in polymyalgia rheumatica. If approved, the company said Cosentyx would be the first IL-17A inhibitor licensed in Europe for adults with the condition, providing a treatment option after steroids. The announcement is listed in the Novartis newsroom.
